Abagovomab
From Wikipedia, the free encyclopedia
|
Abagovomab
|
|
|
|
|
| Source | mouse |
| Target | ? |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Abagovomab is a mouse monoclonal antibody is an anti-idiotype is to treat Homo sapiens cancer. It binds to the antigens 125, CA 125, MUC-16.
[edit] External link
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Abagovomab, Afelimomab, Altumomab, Anatumomab mafenatox, Arcitumomab, Bectumomab, Besilesomab, Biciromab brallobarbital, Capromab, Detumomab, Dorlimomab aritox, Edobacomab, Edrecolomab, Elsilimomab, Enlimomab, Enlimomab pegol, Epitumomab, Epitumomab cituxetan, Fanolesomab, Faralimomab, Gavilimomab, Ibritumomab tiuxetan, Igovomab, Imciromab, Inolimomab, Lemalesomab, Maslimomab, Minretumomab, Mitumomab, Nacolomab tafenatox, Nerelimomab, Nofetumomab merpentan, Odulimomab, Oregovomab, Pemtumomab, Pintumomab, Satumomab, Sulesomab, Taplitumomab paptox, Telimomab aritox, Tositumomab, Vepalimomab, Zolimomab aritox
